Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas

Clinical Neuropathology

Volumn 27, Issue 1, 2008, Pages 13-20

  Bhagavathi, S ^a   Sharathkumar, A ^b   Hunter, S ^a   Sung, L ^a   Kanhere, R ^a   Venturina, M D ^a   Wilson, J D ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Activated B cell type; Bcl 2; Germinal B cell type; Immunohistochemistry; MIB 1; Primary CNS lymphoma

Indexed keywords

CD20 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL 6;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GERM LAYER; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; NONHODGKIN LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 38549175241     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NPP27013     Document Type: Article

References (27)

1. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, Deangelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005; 23: 5034-5043.
2. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, Deangelis LM. Primary central nervous system lymphoma: the memorial sloan-kettering cancer center prognostic model. J Clin Oncol. 2006; 24: 5711-5715.
3. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503-511.
4. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006; 24: 1281-1288.
5. Camilleri-Broet S, Martin A, Moreau A, Angonin R, Henin D, Gontier MF, Rousselet MC, Caulet-Maugendre S, Cuilliere P, Lefrancq T, Mokhtari K, Morcos M, Broet P, Kujas M, Hauw JJ, Desablens B, Raphael M. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'Etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. 1998; 110: 607-612.
6. Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, Colombat P, Hoang-Xuan K, Martin A. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006; 107: 190-196.
7. CBTRUS (Central Brain Tumor Registry of the United States). Primary Brain Tumors in The United States 1995-1999: Statistically report. Chicago, IL: CBTRUS; 2002-2003. 2006.
8. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, Kajdacsy-Balla A, Perkins SL. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphomas. Am J Surg Pathol. 2004; 28: 464-470.
9. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001; 13: 325-334.
10. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003; 21: 266-272.
11. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med. 1993; 119: 1093-1104.
12. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997; 90: 244-251.
13. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275-282.
14. Hoang-Xuan K, Camilleri-Broet S, Soussain C. Recent advances in primary CNS lymphoma. Curr Opin Oncol. 2004; 16: 601-606.
15. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, Gascoyne R., Campo E, Ott G, Muller-Hermelink HK, Delabie J, Jaffe ES, Grogan TM, Connors JM, Vose JM, Armitage JO, Staudt LM, Chan WC. Bcl-2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 961-968.
16. Jaffe E, Harris N, Stein H et al. World Health Organization classification of tumors: pathology and genetics: tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
17. Larocca LM, Capello D, Rinelli A, Nori S, Antinori A, Gloghini A, Cingolani A, Migliazza A, Saglio G, Cammilleri-Broet S, Raphael M, Carbone A, Gaidano G. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B-cells. Blood. 1998; 92: 1011-1019.
18. Llanos M, Alvarez-Arguelles H, Aleman R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of ki-67 nuclear proliferative antigen, bc 1-2 protein and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol. 2001; 18: 15-22.
19. Miller TB, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foukar-Kjeldsberg CR, Levy N, Nathwani BN. Prognostic significance of the ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group Trial. Blood. 1994; 83: 1460-1466.
20. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes Bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003; 101: 4279-4284.
21. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003; 97: 2462-2473.
22. Nikiforova MN, His ED, Braziel RM, Gulley ML, Leonard DGB, Nowak JA, Tubbs RR, Vance GH, Van Deerlin VM. Detection of clonal IgH gene rearrangements. Archives of Pathology & Laboratory Medicine. 2007; 131: 185-189.
23. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med., 2002; 346: 1937-1947.
24. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol. 1999; 43: 199-201.
25. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001; 19: 742-749.
26. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B-cells with ongoing mutational activity. Blood. 1999; 94: 1738-1746.
27. Tominaga K, Yamaguchi Y, Nozawa Y Abe M, Wakasa H. Proliferation in non-Hodgkin's lymphomas as determinated by immunohistochemical double staining for ki-67. Hematol Oncol. 1993; 10: 163-169.